Positioned for the expanding cannabis market
Independent Investment Research
Independent Investment Research
Creso Pharma Limited will develop, register and commercialise food grade and medicinal grade cannabis, initially supplying food supplements for animals, entering the human food supplement market in the short term, and later supplying medicinal cannabis based products for chronically ill patients. Governments are progressively legalising the use of medicinal cannabis with 17 countries having decriminalised medicinal cannabis. An investment in Creso Pharma Ltd is considered speculative at this stage, based on the company’s low revenue base and the competitive environment. Independent Investment Research expects the company’s strong management, global strategies and low capital cost business model will provide the company with significant competitive advantages. At this early stage we have not attributed a price target.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
Already have an account? Sign in here
Advertisement
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both listed and unlisted. The research is for Financial Planners, Brokers, Family Offices and Fund Managers. IIR distributes its research in Asia, United States and Europe. Importantly, IIR does not participate in any corporate or capital raising activity or advice and therefore it does not have any inherent bias that may result from research that is linked to any corporate/ capital raising activity. Analyst remuneration is not linked to stock/ fund performance, in fact the remuneration does not have any nexus to company/ fund pricing, performance or like. Analyst are prohibited to participate in any promotional activity that may compromise the independent of its research.
IIR was established in 2004 under Aegis Equities Research Group of companies to provide investment research to a select group of retail and wholesale clients. Since March 2010, IIR (the Aegis Equities business was sold to Morningstar) has operated independently from Aegis by former Aegis senior executives/shareholders to provide clients with unparalleled research that covers listed and unlisted managed investments, listed companies, structured products, and IPOs.
IIR takes great pride in the quality and independence of our analysis, underpinned by high caliber staff and a transparent, proven and rigorous research methodology.
Never miss an update
Get the latest insights from me in your inbox when they’re published.
1 stock mentioned
Independent Investment Research
Independent Investment Research
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...
Expertise
Independent Investment Research
Independent Investment Research
Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...
Please sign in to comment on this wire.